June Laffey was appointed to the new position of Executive Vice President, Chief Creative Officer, McCann Health New York.
Illegal shipments of the powerful and addictive opioid fentanyl are pouring into the United States by mail from China.
Spark Therapeutics licensed rights to its breakthrough gene therapy Luxturna outside the United States to Switzerland-based Novartis.
The use of artificial intelligence to address health concerns is a growing field and tech giant Google is backing Chinese company XtalPi Inc. in its goal of using AI to help with drug design.
The biopharma industry is perceived to be at a turning point, where companies have the opportunity to meaningfully adapt their innovation strategy and take advantage of major technological advances and new therapeutic modalities.
Philanthropist Bill Gates’ fund is aimed at wiping out the disease in seven of the region’s countries and the Dominican Republic.
A Novartis executive said the Swiss company’s heart failure medicine Entresto could be used more widely in the future.
Pfizer Inc. announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera (rituximab-EU), met its primary endpoint.
Puma Biotechnology Inc. said a European regulatory panel indicated it was unlikely to provide a positive opinion on the company’s breast cancer drug.